Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00499460 · ClinicalTrials.gov registry record · Phase 4

Effects of Garlic Supplements on Opioids in Healthy Volunteers

A Phase 4 study of Healthy, no Evidence of Disease, sponsored by Fred Hutchinson Cancer Center.

Completed
Registry status
Phase 4
Development phase
15
Enrollment target
1
Study location

NCT00499460 is a Phase 4 study of Healthy, no Evidence of Disease that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 15 participants, below the 176-participant average among 11 other Healthy, no Evidence of Disease trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00499460, a Phase 4 study of Healthy, no Evidence of Disease, has completed, sponsored by Fred Hutchinson Cancer Center.

COMPLETED
Registry status
Phase 4
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Garlic supplements may alter the pharmacokinetics of oxycodone, thereby affecting its effectiveness as an opioid analgesic for the relief of moderate or severe pain. PURPOSE: This randomized phase 4 trial is studying how garlic supplements may change the pharmacokinetics of oxycodone and its analgesic and side effects in healthy volunteers.

Interventions

  • DIETARY_SUPPLEMENT garlic powder tablets
  • DRUG oxycodone

Study Locations (1)

Washington

  • Fred Hutchinson Cancer Research Center - Seattle

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2006-11
Est. Completion 2008-08
Phase Phase 4

Sponsor

Fred Hutchinson Cancer Center

483 total trials

What the Registry Record Tells You About NCT00499460

The ClinicalTrials.gov registry entry for NCT00499460 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 176-participant average among 11 other Healthy, no Evidence of Disease trials with a reported enrollment target (91% lower). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy, no Evidence of Disease appearing as the primary indexed condition, and to 2 interventions - of which garlic powder tablets is the first listed.

NCT00499460 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT00499460 about?

NCT00499460 is a clinical study titled "Effects of Garlic Supplements on Opioids in Healthy Volunteers". RATIONALE: Garlic supplements may alter the pharmacokinetics of oxycodone, thereby affecting its effectiveness as an opioid analgesic for the relief of moderate or severe pain. PURPOSE: This randomized phase 4 trial is studying how garlic supplements may change the pharmacokinetics of oxycodone and...

What is the current status of trial NCT00499460?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2006-11. Estimated completion is 2008-08.

What conditions does trial NCT00499460 study?

This clinical trial studies the following conditions: Healthy, no Evidence of Disease.

What interventions are being tested in trial NCT00499460?

The interventions under investigation include: garlic powder tablets (DIETARY_SUPPLEMENT), oxycodone (DRUG).

Who is sponsoring clinical trial NCT00499460?

This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00499460 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy, no Evidence of Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.